Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial by Tadeusz Robak, Krzysztof Jamroziak, Joanna Gora-Tybor, Jerzy Z. Blonski, Marek Kasznicki, Jadwiga Dwilewicz-Trojaczek, Elzbieta Wiater, Andrzej Zdunczyk, Jacek Dybowicz, Anna Dmoszynska, Maria Wojtaszko, Barbara Zdziarska, Malgorzata Calbecka, Aleksandra Kostyra, Andrzej Hellmann, Krzysztof Lewandowski, Beata Stella-Holowiecka, Kazimierz Sulek, Krzysztof Gawronski, Aleksander B. Skotnicki, Wieslaw Nowak, Krystyna Zawilska, Lucyna Molendowicz-Portala, Janusz Kloczko, Jarosław Sokolowski, Krzysztof Warzocha, Ilona Seferyńska, Bernardeta Ceglarek, and Lech Konopka Blood Volume 109(9):3672-3675 May 1, 2007 ©2007 by American Society of Hematology
Comparison of clinical activities of 2 schedules of 2-CdA administration in newly diagnosed patients with hairy cell leukemia tested in the study. Comparison of clinical activities of 2 schedules of 2-CdA administration in newly diagnosed patients with hairy cell leukemia tested in the study. (A) Response to 2-CdA therapy. (B) Overall survival analysis. (C) Progression-free survival analysis. Tadeusz Robak et al. Blood 2007;109:3672-3675 ©2007 by American Society of Hematology